- Home
- DCGO vs TLSI Comparison
DCGO vs TLSI Comparison
Compare DCGO & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCGO
- TLSI
- Stock Information
- Founded
- DCGO 2015
- TLSI 2010
- Country
- DCGO United States
- TLSI United States
- Employees
- DCGO N/A
- TLSI N/A
- Industry
- DCGO Managed Health Care
- TLSI Medical Specialities
- Sector
- DCGO Health Care
- TLSI Health Care
- Exchange
- DCGO Nasdaq
- TLSI Nasdaq
- Market Cap
- DCGO 139.7M
- TLSI 150.0M
- IPO Year
- DCGO N/A
- TLSI N/A
- Fundamental
- Price
- DCGO $1.58
- TLSI $5.05
- Analyst Decision
- DCGO Strong Buy
- TLSI Strong Buy
- Analyst Count
- DCGO 4
- TLSI 5
- Target Price
- DCGO $3.78
- TLSI $10.90
- AVG Volume (30 Days)
- DCGO 454.9K
- TLSI 112.5K
- Earning Date
- DCGO 11-06-2025
- TLSI 08-12-2025
- Dividend Yield
- DCGO N/A
- TLSI N/A
- EPS Growth
- DCGO N/A
- TLSI N/A
- EPS
- DCGO N/A
- TLSI N/A
- Revenue
- DCGO $435,968,564.00
- TLSI $35,990,000.00
- Revenue This Year
- DCGO N/A
- TLSI $56.79
- Revenue Next Year
- DCGO N/A
- TLSI $54.15
- P/E Ratio
- DCGO N/A
- TLSI N/A
- Revenue Growth
- DCGO N/A
- TLSI 45.50
- 52 Week Low
- DCGO $1.23
- TLSI $3.42
- 52 Week High
- DCGO $5.68
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- DCGO 50.17
- TLSI 55.11
- Support Level
- DCGO $1.48
- TLSI $4.80
- Resistance Level
- DCGO $1.60
- TLSI $5.24
- Average True Range (ATR)
- DCGO 0.07
- TLSI 0.35
- MACD
- DCGO -0.01
- TLSI 0.02
- Stochastic Oscillator
- DCGO 37.25
- TLSI 72.18
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.